Neutrophil-to-lymphocyte ratio predicts survival of patients with rectal cancer receiving neo-adjuvant chemoradiation followed by radical resection: a meta-analysis

References

• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403.
   PubMed Web of Science ®Google Scholar
• Powell AG, Wallace R, McKee RF, et al. The relationship between tumor site, clinicopathological characteristics and cancer-specific survival in patients undergoing surgery for colorectal cancer. Colorectal Dis. 2012;14:1493–1499.
   PubMed Web of Science ®Google Scholar
• Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711–717.
   PubMed Web of Science ®Google Scholar
• Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29–42.
   PubMed Web of Science ®Google Scholar
• Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 May;22(5):702–715.
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–454.
   PubMed Web of Science ®Google Scholar
• Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Ott Hosp Res Inst. 2014. Available from http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
   Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
   PubMed Web of Science ®Google Scholar
• Carruthers R, Tho LM, Brown J, et al. Systemic inflammatory response undergoing preoperative chemoradiation for locally advanced rectal cancer. Colorectal Dis. 2012;14:e701–e707.
   PubMed Web of Science ®Google Scholar
• Kim IY, You SH, Kim YW. Neutrophil-lymphocyte ratio predicts pathologic tumor response and survival after preoperative chemoradiation for rectal cancer. BMC Surgery. 2014;14(1):94.
   PubMedGoogle Scholar
• Shen L, Zhang H, Liang L, et al. Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. Radiat Oncol. 2014;9:295.
   PubMed Web of Science ®Google Scholar
• Nagasaki T, Akiyoshi T, Fujimoto Y, et al. Prognostic impact of neutrophil-to-lymphocyte ratio in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy. Dig Surg. 2015;32:496–503.
   PubMed Web of Science ®Google Scholar
• Toiyama Y, Inoue Y, Kawamura M, et al. Elevated platelet count as predictor of recurrence in rectal cancer patients undergoing preoperative chemoradiotherapy followed by surgery. Int Surg. 2015;100:199–207.
   PubMed Web of Science ®Google Scholar
• Hodek M, Sirak I, Ferko A, et al. Neoadjuvant chemoradiotherapy of rectal carcinoma. Baseline hematologic parameters influencing outcomes. Strahlenther Onkol. 2016;192:632–640
   PubMed Web of Science ®Google Scholar
• Khan AA, Akritidis G, Pring T, et al. The neutrophil-to-lymphocyte ratio as a marker of lymph node status in patients with rectal cancer. Oncology. 2016;91:69–77.
   PubMed Web of Science ®Google Scholar
• Lino-Silva LS, Salcedo-Hernandez RA, Ruiz-Garcia EB, et al. Pre-operative neutrophils/lymphocyte ratio in rectal cancer patients with preoperative chemoradiotherapy. Med Arch. 2016;70(4):256–260.
   PubMedGoogle Scholar
• Shen J, Zhu Y, Wu W, et al. Prognostic role of neutrophil-to-lymphocyte ratio in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Med Sci Monit. 2017;23:315–324.
   PubMed Web of Science ®Google Scholar
• Sung SY, Son SH, Park EY, et al. Prognosis of locally advanced rectal cancer can be predicted more accurately using pre- and post-chemoradiotherapy neutrophil-lymphocyte ratios in patients who received preoperative chemoradiotherapy. PLoS ONE. 2017;12:e0173955.
   PubMed Web of Science ®Google Scholar
• Zhao J, Xu J, Zhang R. Clinical and prognostic significance of pathological and inflammatory markers in mucinous rectal cancer patients receiving neoadjuvant chemoradiation therapy and curative surgery. Med Sci Monit. 2017;23:4826–4833.
   PubMed Web of Science ®Google Scholar
• Kim TG, Park W, Kim H, et al. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in rectal cancer patients following neoadjuvant chemoradiotherapy. Tumori J. 2018;105(5):434–440.
   PubMed Web of Science ®Google Scholar
• Vallard A, Garcia M-A, Diao P, et al. Outcomes prediction in pre-operative radiotherapy locally advanced rectal cancer: leucocyte assessment as immune biomarker. Oncotarget. 2018;9(32):22368–22382.
   PubMedGoogle Scholar
• Ward WH, Goel N, Ruth KJ, et al. Predictive value of leukocyte- and platelet-derived ratios in rectal adenocarcinoma. J Surg Res. 2018;232:275–282.
   PubMed Web of Science ®Google Scholar
• Dudani S, Marginean H, Tang PA, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation. BMC Cancer. 2019;19:664.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li J, Peng Q, et al. Association of markers of systemic and local inflammation with prognosis of patients with rectal cancer who received neoadjuvant radiotherapy. Cancer Manage Res. 2019;11:191–199.
   PubMed Web of Science ®Google Scholar
• Fulop ZZ, Fulop RL, Gurzu S, et al. Prognostic impact of the neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratio, in patients with rectal cancer: a retrospective study of 1052 patients. J Pers Med. 2020;10:173.
   PubMed Web of Science ®Google Scholar
• Ke T-M, Lin L-C, Huang -C-C, et al. High neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predict poor survival in rectal cancer receiving concurrent chemoradiotherapy. Medicine (Baltimore). 2020;99:17.
   Web of Science ®Google Scholar
• Lee JH, Kang B-H, Song C, et al. Microsatellite instability correlated inflammatory markers and their prognostic value in the rectal cancer following neoadjuvant chemoradiotherapy: a hypothesis-generating study. Vivo. 2020;34:2119–2126.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu X, Xu M, et al. Prognostic value of pretreatment systemic inflammatory markers in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy. Sci Rep. 2020;10:8017.
   PubMed Web of Science ®Google Scholar
• Huang C-M, Huang M-Y, Tsai H-L, et al. Pretreatment neutrophil-to-lymphocyte ratio associated with tumor recurrence and survival in patients achieving a pathological complete response following neoadjuvant chemoradiotherapy for rectal cancer. Cancers (Basel). 2021;13:4589.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen L, Zhang B, et al. Pretreatment inflammatory-nutritional biomarkers predict responses to neoadjuvant chemoradiotherapy and survival in locally advanced rectal cancer. Front Oncol. 2021;11:639909.
   PubMed Web of Science ®Google Scholar
• Aires F, Rodrigues D, Pineiro Lamas M, et al. C-reactive protein as predictive biomarker for response to chemoradiotherapy in patients with locally advanced rectal cancer: a retrospective study. Cancers (Basel). 2022;14:491.
   PubMed Web of Science ®Google Scholar
• An SH, Kim IY. Can pretreatment platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios predict long-term oncologic outcomes after preoperative chemoradiation followed by surgery for locally advanced rectal cancer? Ann Coloproctol. 2022;38(3):253–261.
   PubMed Web of Science ®Google Scholar
• Ergen SA, Barlas C, Yildirim C, et al. Prognostic role of peripheral neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in patients with rectal cancer undergoing neoadjuvant chemoradiotherapy. J Gastroint Cancer. 2022;53:151–160
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang L, Gou Y, et al. The combination of pre-neoadjuvant chemoradiotherapy inflammation biomarkers could be a prognostic marker for rectal cancer patients. Sci Rep. 2022;12:4286.
   PubMed Web of Science ®Google Scholar
• Jung SW, Park IJ, Oh SH, et al. Association of immunologic markers from complete blood counts with the response to preoperative chemoradiotherapy and prognosis in locally advanced rectal cancer. Oncotarget. 2017;8(35):59757–59765.
   PubMedGoogle Scholar
• Braun LH, Baumann D, Zwirner K, et al. Neutrophil-to-lymphocyte ratio in rectal cancer – novel biomarker of tumor immunogenicity during radiotherapy or confounding variable? Int J Mol Sci. 2019;20:2448.
   PubMed Web of Science ®Google Scholar
• Cha YJ, Park EJ, Baik SH, et al. Prognostic impact of persistent lower neutrophil-to-lymphocyte ratio during preoperative chemoradiotherapy in locally advanced rectal cancer patients: a propensity score matching analysis. PloS ONE. 2019;14(3):e0214415.
   PubMed Web of Science ®Google Scholar
• Jeon BH, Shin US, Moon SM, et al. Neutrophil to lymphocyte ratio: a predictive marker for treatment outcomes in patients with rectal cancer who underwent neoadjuvant chemoradiation followed by surgery. Ann Coloproctol. 2019;35(2):100–106.
   PubMed Web of Science ®Google Scholar
• Lu S, Liu Z, Zhou X, et al. Preoperative fibrinogen-albumin ratio index (FARI) is a reliable prognosis and chemoradiotherapy sensitivity predictor in locally advanced rectal cancer patients undergoing radical surgery following neoadjuvant chemoradiotherapy. Cancer Manage Res. 2020;12:8555–8568.
   PubMed Web of Science ®Google Scholar
• Hamid HKS, Davis GN, Trejo-Avila M, et al. Prognostic and predictive value of neutrophil-to-lymphocyte ratio after curative rectal cancer resection: a systematic review and meta-analysis. Surg Oncol. 2021;37:101556.
   PubMed Web of Science ®Google Scholar
• Dong Y-W, Shi Y-Q, He L-W, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in rectal cancer: a meta-analysis. Oncol Targets Ther. 2016;9:3127–3134.
   PubMed Web of Science ®Google Scholar
• Li X, Dai D, Chen B, et al. The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: a systematic review and meta-analysis. J Cancer. 2018;9:861–871.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kim K, Park HJ. Meta-analysis on the neutrophil-lymphocyte ratio in rectal cancer treated with preoperative chemoradiotherapy: prognostic value of pre- and post-chemoradiotherapy neutrophil-lymphocyte ratio. Front Oncol. 2022;12:778607.
   PubMed Web of Science ®Google Scholar
• Imtiaz F, Shafique K, Mirza SS, et al. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med. 2012;5:2.
   PubMedGoogle Scholar
• Howard R, Scheiner A, Kanetsky PA, et al. Sociodemographic and lifestyle factors associated with the neutrophil-to-lymphocyte ratio. Ann Epidemiol. 2019;38:11–21.e6.
   PubMed Web of Science ®Google Scholar
• Chen Z-Y, Raghav K, Lieu CH, et al. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer. 2015;112:1088–1097.
   PubMed Web of Science ®Google Scholar
• Cheng H, Luo G, Lu Y, et al. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Pancreatol. 2016;16:1080–1084.
   PubMed Web of Science ®Google Scholar
• Ohki S, Shibata M, Gonda K, et al. Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer. Oncol Rep. 2012;28:453–458.
   PubMed Web of Science ®Google Scholar
• Kitayama J, Yasuda K, Kawai K, et al. Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer. BMC Cancer. 2011;11:64.
   PubMed Web of Science ®Google Scholar
• Santos MD, Silva C, Rocha A, et al. Predictive clinical model of tumor response after chemoradiation in rectal cancer. Oncotarget. 2017;8(35):58133–58151.
   PubMedGoogle Scholar
• Mbanu P, Vasquez Osorio E, Mistry H, et al. Clinico-pathological predictors of clinical complete response in rectal cancer. Cancer Treat Res Commun. 2022;31:100540.
   PubMedGoogle Scholar
• Pages F, Kirilovsky A, Mlecnuk B, et al. In situ cytotoxic and memory T predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27:5944–5951.
   PubMed Web of Science ®Google Scholar
• Lim YJ, Koh J, Kim S, et al. Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes identified patients with poor prognosis in rectal cancer: a matched comparison analysis. Int J Radiat Oncol Biol Phys. 2017;99:1216–1224.
   PubMed Web of Science ®Google Scholar
• Ishikawa D, Nishi M, Takasu C, et al. The role of neutrophil-to-lymphocyte ratio on the effect of CRT for patients with rectal cancer. Vivo. 2020;34:863–868.
   PubMed Web of Science ®Google Scholar
• Kim J, Sohn K-A, Kwak J-H, et al. A novel scoring system for response of preoperative chemoradiotherapy in locally advanced rectal cancer using early-treatment blood features derived from machine learning. Front Oncol. 2021;11:790894.
   PubMed Web of Science ®Google Scholar
• Yang G, Chang JS, Choi JE, et al. Association of neutrophil-to-lymphocyte ratio, radiotherapy fractionation/technique, and risk of development of distant metastasis among patients with locally advanced rectal cancer. Radiat Oncol. 2022;17:100.
   PubMed Web of Science ®Google Scholar
• Lai S, Huang L, Luo S, et al. Systemic inflammatory indices predict tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Oncol Lett. 2020;20:2763–2770.
   PubMed Web of Science ®Google Scholar
• Lee IH, Hwang S, Lee SJ, et al. Systemic inflammatory response after preoperative chemoradiotherapy can affect oncologic outcomes in locally advanced rectal cancer. Anticancer Res. 2017;37:1459–1466.
   PubMed Web of Science ®Google Scholar
• Yang Y, Tian W, Su L, et al. Tumor-infiltrating cytotoxic T cells and tumor-associated macrophages correlate with the outcome of neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Front Oncol. 2021;11:743540.
   PubMed Web of Science ®Google Scholar
• Chen -C-C, Wu M-L, Huang K-C, et al. The effects of neoadjuvant treatment on the tumor microenvironment in rectal cancer: implications for immune activation and therapy response. Clin Colorectal Cancer. 2020;19(4):e164–e180.
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Wyewicz L, Tiret E, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl4):iv22–iv40.
   PubMedGoogle Scholar
• Colloca G, Venturino A, Vitucci P. Pre-treatment carcinoembryonic antigen and outcome of patients with rectal cancer receiving neo-adjuvant chemo-radiation and surgical resection: a systematic review and meta-analysis. Med Oncol. 2017;34:177.
   PubMed Web of Science ®Google Scholar
• He W-Z, Hu W-M, Kong P-F, et al. Systemic neutrophil lymphocyte ratio and mismatch repair status in colorectal cancer patients: correlation and prognostic value. J Cancer. 2018;9(17):3093–3100.
   PubMed Web of Science ®Google Scholar
• Yasui K, Kondou R, Iizuka A, et al. Effect of preoperative chemoradiotherapy on the immunological status of rectal cancer patients. J Radiation Res. 2020;61(5):766–775.
   PubMed Web of Science ®Google Scholar